Bỉ - Tiếng Hà Lan - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pramipexoldihydrochloridemonohydraat 0,75 mg - eq. pramipexol 0,52 mg - tablet met verlengde afgifte - 0,52 mg - pramipexoldihydrochloridemonohydraat 0.75 mg - pramipexole

Bỉ - Tiếng Hà Lan - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pramipexoldihydrochloridemonohydraat 1,5 mg - eq. pramipexol 1,05 mg - tablet met verlengde afgifte - 1,05 mg - pramipexoldihydrochloridemonohydraat 1.5 mg - pramipexole

Bỉ - Tiếng Hà Lan - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pramipexoldihydrochloridemonohydraat 2,25 mg - eq. pramipexol 1,57 mg - tablet met verlengde afgifte - 1,57 mg - pramipexoldihydrochloridemonohydraat 2.25 mg - pramipexole

Bỉ - Tiếng Hà Lan - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pramipexoldihydrochloridemonohydraat 3 mg - eq. pramipexol 2,1 mg - tablet met verlengde afgifte - 2,10 mg - pramipexoldihydrochloridemonohydraat 3 mg - pramipexole

Bỉ - Tiếng Hà Lan - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pramipexoldihydrochloridemonohydraat 3,75 mg - eq. pramipexol 2,62 mg - tablet met verlengde afgifte - 2,62 mg - pramipexoldihydrochloridemonohydraat 3.75 mg - pramipexole

Bỉ - Tiếng Hà Lan - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pramipexoldihydrochloridemonohydraat 4,5 mg - eq. pramipexol 3,15 mg - tablet met verlengde afgifte - 3,15 mg - pramipexoldihydrochloridemonohydraat 4.5 mg - pramipexole

Bỉ - Tiếng Hà Lan - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - pramipexoldihydrochloridemonohydraat 0,25 mg - eq. pramipexol 0,18 mg - tablet - 0,18 mg - pramipexoldihydrochloridemonohydraat - pramipexole

Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastische middelen - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - carcinoom, niet-kleincellige long - antineoplastische middelen - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoom, niet-kleincellige long - antineoplastische middelen - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.